Infant Bacterial Therapeutics
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
IBT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008015242 (+3 more)
- LEI:
- 2138008KVBXCRJGP6Z26
- Country:
- Sweden
- Address:
- Bryggargatan 10, 111 21 Stockholm
- Website:
- https://ibtherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Infant Bacterial Therapeutics (IBT) is a clinical-stage pharmaceutical company focused on developing innovative medicines for rare diseases affecting premature infants. The company's primary mission is to prevent necrotizing enterocolitis (NEC), a severe and often fatal inflammatory bowel condition. IBT's lead drug candidate, IBP-9414, is a novel live bacterial therapeutic designed to modulate the infant gut microbiome. IBP-9414, which has received Breakthrough Therapy Designation, is currently being evaluated in a pivotal Phase 3 clinical trial known as 'The Connection Study'. IBT's approach leverages its expertise in using live bacteria as active pharmaceutical substances to address significant unmet medical needs in this vulnerable patient population.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-25 18:41 |
Legal Proceedings Report
IBT changes the IBP-9414 pathway for approval following discussions with the FDA
|
English | 52.4 KB | ||
| 2025-11-25 18:41 |
Legal Proceedings Report
IBT byter väg för marknadsgodkännande för IBP-9414 efter diskussioner med FDA
|
Swedish | 52.6 KB | ||
| 2025-11-13 07:30 |
Quarterly Report
|
Swedish | 602.4 KB | ||
| 2025-11-13 07:30 |
Quarterly Report
|
English | 565.8 KB | ||
| 2025-10-20 10:35 |
Board/Management Information
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomina…
|
English | 39.9 KB | ||
| 2025-10-20 10:35 |
Board/Management Information
Infant Bacterial Therapeutics AB (publ) meddelar att valberedningen inför årsst…
|
Swedish | 39.6 KB | ||
| 2025-08-20 08:00 |
Interim / Quarterly Report
|
Swedish | 586.0 KB | ||
| 2025-08-20 08:00 |
Interim / Quarterly Report
|
English | 565.3 KB | ||
| 2025-05-08 17:45 |
AGM Information
Annual General Meeting of Infant Bacterial Therapeutics
|
English | 41.0 KB | ||
| 2025-05-08 17:45 |
AGM Information
Årsstämma i Infant Bacterial Therapeutics
|
Swedish | 40.6 KB | ||
| 2025-05-07 14:30 |
Quarterly Report
|
Swedish | 550.1 KB | ||
| 2025-05-07 14:30 |
Quarterly Report
|
English | 549.5 KB | ||
| 2025-02-13 08:30 |
Earnings Release
|
Swedish | 577.8 KB | ||
| 2025-02-13 08:30 |
Annual Report
|
English | 571.2 KB | ||
| 2024-08-28 08:30 |
Interim / Quarterly Report
|
Swedish | 578.3 KB |
Automate Your Workflow. Get a real-time feed of all Infant Bacterial Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Infant Bacterial Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Infant Bacterial Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-14 | Maria Ekdahl | Other | Buy | 500 | 17,000.00 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 839 | 79,033.80 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 161 | 15,134.00 SEK |
| 2023-06-09 | Maria Ekdahl | Other | Buy | 1,086 | 49,956.00 SEK |
| 2023-05-23 | Anders Kronström | Other | Buy | 1,329 | 56,482.50 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 851 | 36,593.00 SEK |
| 2023-05-23 | Maria Ekdahl | Other | Buy | 465 | 19,995.00 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,377.20 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,269.92 SEK |
| 2023-05-22 | Maria Ekdahl | Other | Buy | 709 | 30,487.00 SEK |
Peer Companies
